IL164420A0 - Dry powder composition - Google Patents

Dry powder composition

Info

Publication number
IL164420A0
IL164420A0 IL16442004A IL16442004A IL164420A0 IL 164420 A0 IL164420 A0 IL 164420A0 IL 16442004 A IL16442004 A IL 16442004A IL 16442004 A IL16442004 A IL 16442004A IL 164420 A0 IL164420 A0 IL 164420A0
Authority
IL
Israel
Prior art keywords
dry powder
powder composition
composition
dry
powder
Prior art date
Application number
IL16442004A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL164420A0 publication Critical patent/IL164420A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16442004A 2002-04-13 2004-10-05 Dry powder composition IL164420A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208608.0A GB0208608D0 (en) 2002-04-13 2002-04-13 Composition
PCT/GB2003/001542 WO2003088943A1 (en) 2002-04-13 2003-04-10 Dry powder compositions

Publications (1)

Publication Number Publication Date
IL164420A0 true IL164420A0 (en) 2005-12-18

Family

ID=9934855

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16442004A IL164420A0 (en) 2002-04-13 2004-10-05 Dry powder composition

Country Status (19)

Country Link
US (1) US20050244340A1 (https=)
EP (1) EP1494644A1 (https=)
JP (1) JP2005530733A (https=)
KR (1) KR20040099436A (https=)
CN (1) CN1658839A (https=)
AR (1) AR039409A1 (https=)
AU (1) AU2003217073A1 (https=)
BR (1) BR0309114A (https=)
CA (1) CA2481467A1 (https=)
GB (1) GB0208608D0 (https=)
IL (1) IL164420A0 (https=)
IS (1) IS7500A (https=)
MX (1) MXPA04010080A (https=)
NO (1) NO20044497L (https=)
PL (1) PL373294A1 (https=)
RU (1) RU2004130439A (https=)
TW (1) TW200404008A (https=)
WO (1) WO2003088943A1 (https=)
ZA (1) ZA200408245B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
JP2009513531A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
WO2006086270A1 (en) * 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
SI2046787T1 (sl) 2006-08-01 2011-07-29 Glaxo Group Ltd Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
AU2015296024A1 (en) * 2014-08-01 2017-03-23 Luxena Pharmaceuticals, Inc. Palonosetron formulations and uses thereof
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CN110237373B (zh) * 2018-03-08 2023-06-02 润生药业有限公司 一种生产用于联合用药的药物载体的装置及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
DE3682457D1 (de) * 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JPH04220268A (ja) * 1990-12-19 1992-08-11 Olympus Optical Co Ltd バルーンカテーテル
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
DK0994887T3 (da) * 1997-07-03 2003-03-17 Elan Drug Delivery Ltd Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
AU3664102A (en) * 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
RU2004130439A (ru) 2005-06-10
US20050244340A1 (en) 2005-11-03
AR039409A1 (es) 2005-02-16
WO2003088943A1 (en) 2003-10-30
MXPA04010080A (es) 2004-12-13
GB0208608D0 (en) 2002-05-22
JP2005530733A (ja) 2005-10-13
EP1494644A1 (en) 2005-01-12
IS7500A (is) 2004-10-11
CN1658839A (zh) 2005-08-24
AU2003217073A1 (en) 2003-11-03
BR0309114A (pt) 2005-02-01
ZA200408245B (en) 2007-03-28
CA2481467A1 (en) 2003-10-30
NO20044497L (no) 2004-11-15
TW200404008A (en) 2004-03-16
PL373294A1 (en) 2005-08-22
KR20040099436A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
GB0326632D0 (en) Dry powder formulations
EP1487524A4 (en) INHALER FOR DRY POWDER
HRP20040668A2 (en) Dry powder inhaler
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
EP1566419A4 (en) POWDER COATING
AU2003234909A1 (en) Powder composition
IL164421A0 (en) Dry powder inhalant composition
GB0203421D0 (en) Composition
IL164420A0 (en) Dry powder composition
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
GB2372518B (en) Powder composition
GB0218241D0 (en) Composition
EP1495751A4 (en) hair dye
GB0213767D0 (en) Composition
HK1074384A (en) Dry powder compositions
GB0306084D0 (en) Improved cosmetic composition
GB0203616D0 (en) Composition
HK1074783A (en) Dry powder inhalant composition
GB0213264D0 (en) Improved cosmetic composition
GB0209191D0 (en) Composition
GB0222729D0 (en) Composition
GB0208301D0 (en) Composition
GB0200437D0 (en) Composition